The yin and yang of arterial inflammation

Journal of the American College of Cardiology

Volumn 44, Issue 1, 2004, Pages 50-52

  Mills, Roger ^a   Bhatt, Deepak L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIINFLAMMATORY AGENT; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA;

ARTERIAL INFLAMMATION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; ENDOTHELIUM; FOREARM BLOOD FLOW; HOMEOSTASIS; HORMONE SUBSTITUTION; HUMAN; INFLAMMATION; MACROPHAGE; NOTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROBABILITY; SMOOTH MUSCLE; WEIGHT REDUCTION;

EID: 3242765258     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.04.002     Document Type: Editorial

References (21)

1. Bhatt D.L., Topol E.J. Need to test the arterial inflammation hypothesis. Circulation. 106:2002;136-140
2. Shishehbor M.H., Bhatt D.L., Topol E.J. Using C-reactive protein to assess cardiovascular disease risk. Cleve Clin J Med. 70:2003;634-640
3. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease Application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 107:2003;499-511
4. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 342:2000;836-843
5. Chew D.P., Bhatt D.L., Robbins M.A., et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation. 104:2001;992-997
6. Anguera I., Miranda-Guardiola F., Bosch X., et al. Elevation of serum levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina. Am Heart J. 144:2002;811-817
7. Stumpf C., Lehner C., Yilmaz A., Daniel W.G., Garlichs C.D. Decrease of serum levels of the anti-inflammatory cytokine interleukin-10 in patients with advanced chronic heart failure. Clin Sci (Lond). 105:2003;45-50
8. Girndt M., Kaul H., Sester U., et al. Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney Int. 62:2002;949-955
9. Zee R.Y., Ridker P.M. Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis. 162:2002;217-219
10. Ouchi N., Kihara S., Funahashi T., et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 107:2003;671-674
11. Esposito K., Pontillo A., Di Palo C., et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women A randomized trial. JAMA. 289:2003;1799-1804
12. Chew D.P., Bhatt D.L., Robbins M.A., et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol. 88:2001;672-674
13. Fichtlscherer S, Breuer S, Heeschen C, Dimmeler S, Zeiher AM. Interleukin-10 serum levels and systemic endothelial vasoreactivity in patients with coronary artery disease. J Am Coll Cardiol 2004;44:44-9.
14. Heeschen C., Dimmeler S., Hamm C.W., et al. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation. 107:2003;2109-2114
15. Smith D.A., Irving S.D., Sheldon J., Cole D., Kaski J.C. Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation. 104:2001;746-749
16. Blankenberg S., Luc G., Ducimetiere P., et al. Interleukin-18 and the risk of coronary heart disease in European men The Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation. 108:2003;2453-2459
17. Waehre T., Halvorsen B., Damas J.K., et al. Inflammatory imbalance between IL-10 and TNF-alpha in unstable angina potential plaque stabilizing effects of IL-10. Eur J Clin Invest. 32:2002;803-810
18. Fichtlscherer S., Rosenberger G., Walter D.H., Breuer S., Dimmeler S., Zeiher A.M. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation. 102:2000;1000-1006
19. Blake G.J., Ostfeld R.J., Yucel E.K., et al. Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma An in vivo study with high-resolution MRI. Arterioscler Thromb Vasc Biol. 23:2003;e11-e14
20. Chung E.S., Packer M., Lo K.H., Fasanmade A.A., Willerson J.T. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure Results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 107:2003;3133-3140
21. van Roon J., Wijngaarden S., Lafeber F.P., Damen C., van de Winkel J., Bijlsma J.W. Interleukin 10 treatment of patients with rheumatoid arthritis enhances Fc gamma receptor expression on monocytes and responsiveness to immune complex stimulation. J Rheumatol. 30:2003;648-651